GH Research (GHRS) Stock Price, Quote, News & History | Benzinga

SPY776.77−0.17%QQQ742.25−0.51%BTC/USD83,384.58+2.02%DIA516.17−0.34%GLD380.81−0.35%TLT78.31+0.33%

GH Research PLC (GHRS) Stock Price, Quote, News & History

GHRSNASDAQ

Trade with Public

Trade with Public

$18.97

-1.05-5.24%

Last update: Oct 13, 12:07 PM

OverviewNews Earnings Forecast Price Targets Financials Sentiment Compare Options Stock Report

Key Statistics

Open

$19.88

Close

-

Volume / Avg.

116.58K / 291.14K

Day Range

$18.97 - $18.97

52 Wk Range

12.04 - 31.44

Market Cap

$1.37B

P/E Ratio

-

Dividend Yield

-

Exchange

NASDAQ

RSI

23

Short Interest

6.56%

Days to Cover

5

Recent GH Research PLC News

Why Is GH Research Stock Trading Higher on Thursday?

GH Research and Definium Therapeutics stocks rose after Eli Lilly agreed to buy AtaiBeckley in a deal worth up to $3.8 billion.

Vandana Singh

These Analysts Revise Their Forecasts On GH Research After Q1 Results

GH Research (NASDAQ:GHRS) reported a larger loss than expected in Q1. Analysts lowered price targets, stock fell 3.4%. CEO noted progress in GH001 program.

Avi Kapoor

Nektar Therapeutics, Compass Pathways, Sila Realty Trust And Other Big Stocks Moving Higher On Monday

Nektar Therapeutics (NASDAQ: NKTR) rose on positive results for alopecia treatment. Other top gainers include AVEX, CMPS, ATAI, GHRS, POET, SILA, BLD, INV, MXL, KSPI.

Avi Kapoor

Enveric BioSciences Surges Over 90%, Other Psychedelic Stocks Soar In Monday Pre-Market: What's Going On?

Psychedelic drug maker shares jumped in Monday pre-market after an order from President Donald Trump to speed up psychedelic drug reviews

Namrata Sen

Why TopBuild Shares Are Trading Higher By 20%; Here Are 20 Stocks Moving Premarket

TopBuild Corp (NYSE: BLD) rises in pre-market trading after QXO (NYSE: QXO) agrees to acquire for $17 billion. Shares jump 20.2% to $493.01.

Avi Kapoor

Financials

Quarterly

Annual

Name

Revenue Change
Gross Change
EBITDA Change
EBIT Change
Earnings Change

Cash Flows

Operating Cash Flow (TTM)

-51.70M

Investing Cash Flow (TTM)

33.60M

Financing Cash Flow (TTM)

111.74M

Free Cash Flow (TTM)

-51.84M

Capital Expenditure (TTM)

-138.00K

Net Change in Cash (TTM)

93.64M

Analyst Trends and Forecast

2

May

1

Jul

3

Aug

Buy

Hold

Sell

Strong Sell

Analyst Rating and Forecast

4.3

Buy

Strong Buy

Buy

Hold

Sell

Strong Sell

Valuation Metrics

Enterprise Value

$1.09B

PE Ratio (TTM)

-

PE Ratio (FWD)

-

PEG Ratio (TTM)

-

PS Ratio (TTM)

-

PB Ratio (TTM)

3.82

Earnings Yield % (TTM)

-4.95%

Earnings Yield % (FWD)

-8.44%

EV / EBITDA (TTM)

-

Price / EBITDA (TTM)

-

Price / Free Cash Flow (TTM)

-

Book Value / Share

$5.24

Company Debt

Total Debt

-

LT Debt

-

LT Debt Issuance (TTM)

-

LT Debt Repayment (TTM)

-$275.00K

Total Cash

$345.05M

Debt to Equity

0.00

Issuance of Debt (TTM)

-$275.00K

Repayment of Debt (TTM)

-$275.00K